Effects of naltrexone on pain sensitivity and mood in fibromyalgia

No evidence for endogenous opioid pathophysiology

Jarred W. Younger, Alex J. Zautra, Eric T. Cummins

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The pathophysiological mechanisms underlying fibromyalgia are still unknown, although some evidence points to endogenous opioid dysfunction. We examined how endogenous opioid antagonism affects pain and mood for women with and without fibromyalgia. Ten women with fibromyalgia and ten age- and gender-matched, healthy controls each attended two laboratory sessions. Each participant received naltrexone (50mg) at one session, and placebo at the other session, in a randomized and double-blind fashion. Participants were tested for changes in sensitivity to heat, cold, and mechanical pain. Additionally, we collected measures of mood and opioid withdrawal symptoms during the laboratory sessions and at home the night following each session. At baseline, the fibromyalgia group exhibited more somatic complaints, greater sensory sensitivity, more opioid withdrawal somatic symptoms, and lower mechanical and cold pain-tolerance than did the healthy control group. Neither group experienced changes in pain sensitivity due to naltrexone administration. Naltrexone did not differentially affect self-reported withdrawal symptoms, or mood, in the fibromyalgia and control groups. Consistent with prior research, there was no evidence found for abnormal endogenous opioid activity in women with fibromyalgia.

Original languageEnglish (US)
Article numbere5180
JournalPLoS One
Volume4
Issue number4
DOIs
StatePublished - Apr 13 2009

Fingerprint

Naltrexone
Fibromyalgia
narcotics
emotions
pathophysiology
Opioid Analgesics
pain
Pain
Substance Withdrawal Syndrome
signs and symptoms (animals and humans)
Control Groups
placebos
heat
Hot Temperature
Placebos
gender
Research

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Effects of naltrexone on pain sensitivity and mood in fibromyalgia : No evidence for endogenous opioid pathophysiology. / Younger, Jarred W.; Zautra, Alex J.; Cummins, Eric T.

In: PLoS One, Vol. 4, No. 4, e5180, 13.04.2009.

Research output: Contribution to journalArticle

Younger, Jarred W. ; Zautra, Alex J. ; Cummins, Eric T. / Effects of naltrexone on pain sensitivity and mood in fibromyalgia : No evidence for endogenous opioid pathophysiology. In: PLoS One. 2009 ; Vol. 4, No. 4.
@article{f4937a8e574048ed83a42ec559e9bb07,
title = "Effects of naltrexone on pain sensitivity and mood in fibromyalgia: No evidence for endogenous opioid pathophysiology",
abstract = "The pathophysiological mechanisms underlying fibromyalgia are still unknown, although some evidence points to endogenous opioid dysfunction. We examined how endogenous opioid antagonism affects pain and mood for women with and without fibromyalgia. Ten women with fibromyalgia and ten age- and gender-matched, healthy controls each attended two laboratory sessions. Each participant received naltrexone (50mg) at one session, and placebo at the other session, in a randomized and double-blind fashion. Participants were tested for changes in sensitivity to heat, cold, and mechanical pain. Additionally, we collected measures of mood and opioid withdrawal symptoms during the laboratory sessions and at home the night following each session. At baseline, the fibromyalgia group exhibited more somatic complaints, greater sensory sensitivity, more opioid withdrawal somatic symptoms, and lower mechanical and cold pain-tolerance than did the healthy control group. Neither group experienced changes in pain sensitivity due to naltrexone administration. Naltrexone did not differentially affect self-reported withdrawal symptoms, or mood, in the fibromyalgia and control groups. Consistent with prior research, there was no evidence found for abnormal endogenous opioid activity in women with fibromyalgia.",
author = "Younger, {Jarred W.} and Zautra, {Alex J.} and Cummins, {Eric T.}",
year = "2009",
month = "4",
day = "13",
doi = "10.1371/journal.pone.0005180",
language = "English (US)",
volume = "4",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Effects of naltrexone on pain sensitivity and mood in fibromyalgia

T2 - No evidence for endogenous opioid pathophysiology

AU - Younger, Jarred W.

AU - Zautra, Alex J.

AU - Cummins, Eric T.

PY - 2009/4/13

Y1 - 2009/4/13

N2 - The pathophysiological mechanisms underlying fibromyalgia are still unknown, although some evidence points to endogenous opioid dysfunction. We examined how endogenous opioid antagonism affects pain and mood for women with and without fibromyalgia. Ten women with fibromyalgia and ten age- and gender-matched, healthy controls each attended two laboratory sessions. Each participant received naltrexone (50mg) at one session, and placebo at the other session, in a randomized and double-blind fashion. Participants were tested for changes in sensitivity to heat, cold, and mechanical pain. Additionally, we collected measures of mood and opioid withdrawal symptoms during the laboratory sessions and at home the night following each session. At baseline, the fibromyalgia group exhibited more somatic complaints, greater sensory sensitivity, more opioid withdrawal somatic symptoms, and lower mechanical and cold pain-tolerance than did the healthy control group. Neither group experienced changes in pain sensitivity due to naltrexone administration. Naltrexone did not differentially affect self-reported withdrawal symptoms, or mood, in the fibromyalgia and control groups. Consistent with prior research, there was no evidence found for abnormal endogenous opioid activity in women with fibromyalgia.

AB - The pathophysiological mechanisms underlying fibromyalgia are still unknown, although some evidence points to endogenous opioid dysfunction. We examined how endogenous opioid antagonism affects pain and mood for women with and without fibromyalgia. Ten women with fibromyalgia and ten age- and gender-matched, healthy controls each attended two laboratory sessions. Each participant received naltrexone (50mg) at one session, and placebo at the other session, in a randomized and double-blind fashion. Participants were tested for changes in sensitivity to heat, cold, and mechanical pain. Additionally, we collected measures of mood and opioid withdrawal symptoms during the laboratory sessions and at home the night following each session. At baseline, the fibromyalgia group exhibited more somatic complaints, greater sensory sensitivity, more opioid withdrawal somatic symptoms, and lower mechanical and cold pain-tolerance than did the healthy control group. Neither group experienced changes in pain sensitivity due to naltrexone administration. Naltrexone did not differentially affect self-reported withdrawal symptoms, or mood, in the fibromyalgia and control groups. Consistent with prior research, there was no evidence found for abnormal endogenous opioid activity in women with fibromyalgia.

UR - http://www.scopus.com/inward/record.url?scp=65249104842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249104842&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0005180

DO - 10.1371/journal.pone.0005180

M3 - Article

VL - 4

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e5180

ER -